机构：[1]Department of Rheumatology, Peking Union Medical College Hospital,Beijing, China[2]Department of Rheumatology, Jiujiang No.1 People’s Hospital,Jiujiang, China[3]Department of Rheumatology, First Hospital of ShanxiMedical University, Taiyuan, China[4]Department of Rheumatology, People’sHospital of Xinjiang Uygur Autonomous Region, Urumqi, China[5]Departmentof Rheumatology, West China Hospital of Sichuan University, Chengdu, China四川大学华西医院[6]Department of Nephrology, Chenzhou First People’s Hospital, Chenzhou,China[7]Department of Rheumatology, Qilu Hospital of Shandong University,Jinan, China[8]Department of Rheumatology, Jiangxi Pingxiang People’s Hospital,Pingxiang, China[9]Department of Rheumatology, China-Japan FriendshipHospital, Beijing, China[10]Department of Rheumatology, The First AffiliatedHospital of Bengbu Medical College, Bengbu, China[11]Department of Rheumatologyand Immunology, First Affiliated Hospital of Kunming MedicalUniversity, Kunming, China内科科室风湿免疫科昆明医科大学附属第一医院[12]Department of Rheumatology, The First Hospitalof Jilin University, Changchun, China[13]Department of Rheumatology, TheFirst Affiliated Hospital of Baotou Medical College, Inner Mongolia Universityof Science and Technology, Baotou, China内蒙古科技大学包头医学院[14]Department of Rheumatology,The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou,China[15]Shanghai Henlius Biotech, Inc., Shanghai, China
Background: To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate. Methods: In this double-blind, placebo-controlled phase 3 trial, biologic-naive patients with moderate-to-severe active rheumatoid arthritis and inadequate responses to methotrexate were randomized 2:1 to receive 1000 mg HLX01 or placebo intravenously on days 1 and 15. On the first day of weeks 24 and 26, patients in both groups received 1000 mg HLX01 via intravenous infusion. The primary endpoint was the American College of Rheumatology (ACR) 20 response rate at week 24. Secondary endpoints including efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics were assessed up to week 48. Results: Between 28 May 2018 and 11 September 2020, 275 patients were randomized to the HLX01 group (n = 183) or the placebo group (n = 92). At week 24, the proportion of patients achieving ACR20 response was significantly greater in the HLX01 group compared with the placebo group in the intention-to-treat population (60.7% vs 35.9%; P < 0.001) and per-protocol set (60.3% vs 37.1%; P < 0.001). Most secondary efficacy endpoints favoured HLX01 when assessed at weeks 12, 24, 36 and 48. Incidences of treatment-emergent adverse events were similar between groups. Infusion-related reactions occurred more frequently following the initial two doses of HLX01 than the subsequent doses. Conclusions: HLX01 plus methotrexate improved clinical outcomes compared with placebo in Chinese patients with rheumatoid arthritis who had inadequate responses to methotrexate. This treatment regimen was well tolerated, showing comparable safety profiles to placebo.
第一作者机构：[1]Department of Rheumatology, Peking Union Medical College Hospital,Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Zeng Xiaofeng,Liu Ju,Liu Xiumei,et al.Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study[J].ARTHRITIS RESEARCH & THERAPY.2022,24(1):doi:10.1186/s13075-022-02821-x.
APA：
Zeng, Xiaofeng,Liu, Ju,Liu, Xiumei,Wu, Lijun,Liu, Yi...&Zhu, Jun.(2022).Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.ARTHRITIS RESEARCH & THERAPY,24,(1)
MLA：
Zeng, Xiaofeng,et al."Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study".ARTHRITIS RESEARCH & THERAPY 24..1(2022)
医学